

Astellas Makes Announcement about Management Structure

TOKYO, February 7, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the following changes to its management structure effective April 1, 2024.

Top Management

■Addition of Chief Digital & Transformation Officer (CDTO) to the Top Management

Digital initiatives and investments are critical in every part of Astellas business for transformation and to create VALUE creation for patients. We believe that considerations related to digital and business transformation considerations must be built into management strategy formulation and execution. Therefore, Astellas has decided to establish the CDTO as a new member of Top Management. We will appoint Nick Eshkenazi to the CDTO position as of April 1, 2024. He joined Astellas as Chief Digital Officer on November 1, 2023. He brings to Astellas experience driving complex business transformation, and many digital and technology in various industries. He has already made a great impact in terms of enhancing our digital capabilities, and has really helped us think differently about digitalization and transformation. He will be based in Australia.

Top Management (Effective April 1, 2024)

Name	Title
Naoki Okamura	Representative Director, President and Chief Executive Officer (CEO)
Katsuyoshi Sugita	Representative Director, Executive Vice President Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO)
Yoshitsugu Shitaka	Chief Scientific Officer (CScO)
Tadaaki Taniguchi	Chief Medical Officer (CMO)
Hideki Shima	Chief Manufacturing Officer (CMfgO)
Claus Zieler	Chief Commercial Officer (CCO)
Adam Pearson	Chief Strategy Officer (CStO)
Nick Eshkenazi	Chief Digital & Transformation Officer (CDTO)
Atsushi Kitamura	Chief Financial Officer (CFO)
Catherine Levitt	General Counsel (GC)

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+[®] healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201

(Reference)

Name: Nick Eshkenazi

Career History:

November 2023	Chief Digital Officer, Astellas Pharma Inc. (present post)
September 2022	Member Advisory Board, ExoFlare (present post)
September 2020	Group Chief Digital Technology Officer, Woolworths Group
May 2018	Chief Digital Technology Officer, Woolworths Group
May 2015	Director, Technology, Platforms, Innovation, Costco Wholesale
September 2014	Chief Information Officer, Fanatics, Inc.
April 2010	Chief Information Officer, SanMar Corporation
March 2007	Sr. Director, Global Technology & Innovation, PACCAR INC.
March 2003	CTO, Enterprise Solutions and Innovation, USAA
September 2001	JPMorganChase
September 1998	Virtual Learning Technologies, LLP